O
NVAX icon

OrbiMed’s Novavax NVAX Stock Holding History

OrbiMed’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-75,000
Closed -$3.86K – 142
2022
Q2 		$3.86K Buy
+75,000
New +$3.88M 0.07% 120

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

OrbiMed's NVAX Position: Q4 2021 in Review

OrbiMed sold out of Novavax (NVAX) in Q4 2021, closing a stake of 45,580 shares — an estimated $9.45M sold.

OrbiMed first reported a position in NVAX in Q1 2021 and held it in 3 quarters. The position peaked at $42.5M in Q2 2021. 430 funds tracked by Wall St. Rank hold NVAX as of Q4 2021.

  • OrbiMed reported no remaining Novavax position as of Q4 2021 after selling out during the quarter.
  • OrbiMed sold 45,580 Novavax shares in Q4 2021, an estimated $9.45M.
  • OrbiMed first reported a position in Novavax in Q1 2021 and held it in 3 quarters.
  • OrbiMed's Novavax position peaked at $42.5M in Q2 2021.
  • 430 funds tracked by Wall St. Rank held Novavax as of Q4 2021.

Based on OrbiMed's 13F filing for Q4 2021, filed 14 Feb 2022.